鉴定不同性质的人参药物对心力衰竭的生物标志物
Linlin Liu1, Mozhu Jin1, Xueying Han1
1College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China.
Journal of ethnopharmacology
|April 4, 2024
概括
温暖的性质的人参药物对心力衰竭 (HF) 的作用比冷的性质药物更强. 关键的生物标志物,如E2/T比率和特定的荷尔蒙,使其治疗HF的机制有所不同.
科学领域:
- 综合医学是一个整体的医学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 传统中国医学将草药按性质 (热/冷) 分类,用于治疗综合征.
- 人参药物 (例如,人参,红人参) 已知可以调气和治疗潜在的心力衰竭 (HF).
- 不同的人参种类表现出不同的性质,尽管具有相似的人参化物含量,这在理解它们的各种抗HF机制方面构成了挑战.
研究的目的:
- 研究人参药物治疗心力衰竭 (HF) 的药理机制.
- 根据它们固有的性质 (温暖与寒冷) 识别能够区分人参药物的作用的生物标志物.
- 在临床实践中为各种人参药物的差异化应用提供科学基础.
主要方法:
- 通过使用异二醇和特定的饮食诱导心力衰竭 (HF) 的老鼠模型.
- RNA测序分析了差异性基因表达,以了解草药效应.
- 在KEGG路径分析中,发现了与草本性质相关的机制.
- UPLC-QqQ-MS/MS和ELISA测量了包括激素,神经递质和能量代谢物在内的关键生物标志物.
主要成果:
- 所有人参药物都在缓解高血压方面表现出有效性,人参 (GS) 显示出显著的保护作用.
- 强化气功的人参药物主要通过提高上腺激素,T4,cAMP/cGMP水平,并激活乙胆酶 (AchE) 来起作用.
- 温性人参药物调节了特定的孕激素和雄激素,而冷性人参药物影响了不同的雄激素和雌激素水平.
结论:
- 温性人参药物在心力衰竭 (HF) 上表现出比冷性品种更强大的作用.
- 鉴定出E2/T比率,孕激素 (17-OH-PR,17-OH-P,P) 和雄激素 (A4,T) 是区分人参药物机制在HF治疗中的重要生物标志物.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
563
04:27Author Spotlight: Advantages of Pressure-Volume Loop Measurement Method in Cardiovascular Research
Published on: January 12, 2024
501
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
144
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
144
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K